Telix, ANMI to Jointly Develop, Commercialize Prostate Cancer Imaging Agent

Telix, ANMI to Jointly Develop, Commercialize Prostate Cancer Imaging Agent
Australia's Telix Pharmaceuticals has entered a partnership with Belgium's Advanced Nuclear Medicine Ingredients (ANMI) to commercialize ANMI’s 68Ga-HBED-CC-PSMA (68Ga-PSMA-11) kit, used for prostate cancer imaging, in the United States. “Prostate cancer affects one in eight men in the U.S. and the market opportunity is very significant," ANMI co-founder and CEO Ludovic Wouters said in a press release. "We are pleased to be working with Telix to deliver our solution to patients in the U.S.” ANMI's 68Ga-PSMA-11 kit is composed of a small molecule, called PSMA-11, that binds to the prostate-specific membrane antigen (PSMA). PSMA is found in all types of prostatic tissues, but is more prevalent in metastatic prostate cancer, including castrate-resistant prostate cancer. The PSMA-11 in ANMI's kit is attached to 68Ga (gallium), a radioactive chemical element that positron emission tomography (PET) scans can detect, providing improved spatial resolution and easier quantitation. As a result, the 68Ga-PSMA-11 kit allows for a better imaging of the patients' primary tumor and metastasis. “ANMI’s ‘shake and inject’ kit allows for the rapid, room-temperature labelling of the PSMA-11 ligand with gallium. This has become a well-proven approach for imaging prostate cancer and ANMI’s technology makes the process extremely efficient in the clinical setting," said Telix's co-founder and CEO, Dr. Christian Behrenbruch. "ANMI’s radiochemists are the best and brightest in the indu
Subscribe or to access all post and page content.